Kazuo Kubo

KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties

Kazuhide Nakamura, Eri Taguchi, Atsushi Yamamoto et al. · Cancer Research · 2006 · 209 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors:  Synthesis, Structure−Activity Relationships, and Antitumor Activities of <i>N</i>-Phenyl-<i>N</i>‘-{4-(4-quinolyloxy)phenyl}ureas

Kazuo Kubo, Toshiyuki Shimizu, Shin-ichi Ohyama et al. · Journal of Medicinal Chemistry · 2005 · 146 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Survival in long-term haemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy

Toru Shinzato, Shigeru Nakai, T. Akiba et al. · Nephrology Dialysis Transplantation · 1997 · 125 citations · Full text

Medicine, Nephrology, Dialysis +12

Report on the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996

Toru Shinzato, Shigeru Nakai, Takashi Akiba et al. · Kidney International · 1999 · 111 citations · Full text

Medicine, Nephrology, Dialysis +12

A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model

Hiroaki Ohno, Kazuo Kubo, Hideko Murooka et al. · Molecular Cancer Therapeutics · 2006 · 99 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16